Kenneth Reed
Vermögen: 4 Mio $ am 31.05.2026
Vermögen: 4 Mio $ am 31.05.2026
Kenneth Reed is the founder of Prescient Pharma LLC.
Current jobs include Director at Minerva Biotechnologies Corp.
and Independent Director at RedHill Biopharma Ltd. Education history includes an undergraduate degree from Brown University, a doctorate from the University of Medicine & Dentistry of New Jersey, and an undergraduate degree from Harvard Medical School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REDHILL BIOPHARMA LTD. 0,08 % | 27.04.2026 | 42 130 000 ( 0,08 % ) | 4 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| REDHILL BIOPHARMA LTD. | Direktor/Vorstandsmitglied | 15.12.2009 |
Minerva Biotechnologies Corp.
Minerva Biotechnologies Corp. Medical DistributorsDistribution Services Provides medical services | Direktor/Vorstandsmitglied | 21.02.2011 |
| Unternehmen | Position | Ende |
|---|---|---|
Prescient Pharma LLC | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Minerva Biotechnologies Corp.
Minerva Biotechnologies Corp. Medical DistributorsDistribution Services Provides medical services | Distribution Services |
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Medicine & Dentistry of New Jersey
University of Medicine & Dentistry of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RedHill Biopharma Ltd.
RedHill Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provides GI, infectious diseases, medical countermeasures and oncology services | Health Technology |
Prescient Pharma LLC |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen